Evaluating once daily dosing of aminoglycosides: An observational study

Formulary

Volumn 31, Issue 1, 1996, Pages 34-48

  Okpara, Alphonsus U ^a,b   Amaya Diaz, Analiza ^b   Egbunike, Ifeanyi G ^b,c   Maswoswe, Jordan J ^a,b   Enigbokan, Mofolorunso A ^b  

^a Lyndon B Johnson General Hospital   (United States)

^b TEXAS SOUTHERN UNIVERSITY   (United States)

^c Texas S University/Harris County   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; FUROSEMIDE; GENTAMICIN; TOBRAMYCIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; GRAM NEGATIVE INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; OTOTOXICITY; PSEUDOMONAS AERUGINOSA; TREATMENT OUTCOME;

EID: 0030059272     PISSN: 00986909     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hustinix WNM, Hoepleman IM. Aminoglycoside dosage regimens is once daily enough? Clin Pharmacokinet 1993;25 (suppl 6):427-32.
2. Okpara AU, Maswoswe JJ, Egbunike IG, et al. Enforcing an antimicrobial restriction policy through amikacin DUE. P&T 1994;19:375-83.
3. Cuhna BA. Aminoglycosides Current role in antimicrobial therapy. Pharmacotherapy 1988;6.334-50
4. Edson RS, Terrel CL. The aminoglycosides. Mayo Clinic Proceed 1988;66: 1158-64.
5. Gilbert DN. Minireview: Once daily aminoglycoside therapy. Antimicrob Agent Chemother 1991;35:399-405.
6. Nordstrom L, Lerner SA. Single daily dose therapy with aminoglycoside. J Hosp Infect 1991:18(suppl A):117-29.
7. Miyagawa CI. Aminoglycosides in the intensive care unit: An old drug in a dynamic environment New Horizons 1993:2 172-80.
8. Moellering RC Have the beta-lactams rendered the aminoglycosides obsolete for the treatment of serious nosocomial infections? Am J Med 1986:80(suppl 6B):447-57
9. Zhanel GG, Ariano RE. Once daily aminoglycoside dosing: Maintained efficacy with reduced nephrotoxicity. Renal Failure 1992;14:1-9.
10. Vogelman BS, Craig WA. Postantibiotic Effect. J Antimicrob Chemother 1985;15 (suppl A):37-46.
11. Craig WA Post-antibiotic effects in experimental infection models: Relationship to in-vitro phenomena and to treatment of infection in man. J Antimicrob Chemother 1993,31(suppl D).149-58.
12. Craig W. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur J Clin Microbiol Infect Dis 1993,12(suppl 1):6-8.
13. Vogelman B, Craig WA Kinetics of antimicrobial activity. J Pediatr 1986;108. 835-40.
14. Prins JM, Buller HR, Kuiper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993;341:335-9
15. Rodman DP, Maxwell AL, Mcknight T Extended dosing interval for aminoglycosides Am J Hosp Pharm 1994;51. 2016-21
16. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infections in patients with cancer and granulocytopenia. Am J Med 1993;119:584-93.
17. Vanhaeverbeek M, Siska G, Herchueiz A. Pharmacokinetics of once daily ami kacin in elderly patients. J Antimicrobial Chemother 1993;31:185-7.
18. Rodzinski E, Kern WV, Reichle A, et al Once-daily versus thrice daily of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993,31:585-98.
19. Bergeron MG What preclinical data are needed to justify once daily therapy. J Clin Pharmacol 1992;32:698-705.
20. Watling SM, Dasta JF Aminoglycoside dosing considerations in intensive care unit patients. Ann Pharmacother 1993; 27:351-57.
21. Parker SE, Davey PG. Once daily dosing of aminoglycosides. Lancet 1993,341:4-8.
22. Nicolau D. Once-daily aminoglycosides. Conn Med 1992;56:561-3.
23. Strum AW. Netilmicin in the treatment of gram-negative bacteremia: Single versus multiple daily dosage. J Infect Dis 1989;159:931-7.
24. Crockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
25. Bertino JS, Rodvold KA, Destache CJ. Cost considerations in therapeutic drug monitoring of aminoglycosides. Clin Pharmacokinet 1994;26:71-81
26. Beaucaire G, Leroy O, Beuscart C. et al. Clinical and bacteriological efficacy and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother 1991;27(suppl C):21-8.
27. De Vries PJ, Verkooyen RP, Legiut P, et al Prospective randomized study of once daily versus thrice daily netilimicin regimens in patients with intra-abdominal Infections. Eur J Microbiol Infect Dis 1990:9 161-8.
28. Kahimeter G, Dahlager JI. Aminoglycoside toxicity: A review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 1984;13(suppl A):9-22.
29. Fu K, Neu HC. In vitro study of netilimicin compared with other aminoglycosides. J Antimicrob Chemother 1976;10: 526-30.
30. Chan GLC Alternative dosing strategy for aminoglycosides. Impact on efficacy. nephrotoxicity. and ototoxicity. DICP, Ann Pharmacother 1989;23:788-94.
31. Maller R, Ahrne H, Eilard T, et al. Efficacy and safety of amikacin in systemic infections when given as single dose of in two divided daily doses J Infect Dis 1984;149:23-30.
32. Fee WE Gentamicin and tobramycin: Comparison of ototoxicity. Rev Infect Dis 1983;5:S304-13.
33. Brushwood DB Government liable for failure to monitor a patient's serum gentamicin concentration in an army hospital. Am J Hosp Pharm 1992,49:1748-50.
34. Okpara AU, Maswoswe JJ. Emergence of multidrug-resistant isolates of Acinetobacter baumannu Am J Hosp Pharm 1994,51.2671-5.
35. Whelton A. Therapeutic initiatives for the avoidance of aminoglycoside toxicity. J Clin Pharmacol 1985;25.67-81
36. Rybak MJ, Albrecht LM, Boike SC. Chandrasekar PH Nephrotoxicity of vancomycin. alone and with an aminoglycoside. J Antimicrob Chemother 1990,25:679-87.
37. Oparaoji EC, Comwell EE, Hekmat E, et al. Aminoglycoside volume of distribution in postoperative patients with septic shock. Clin Pharm 1993.12:131-4.